See the DrugPatentWatch profile for Linzess

Linzess Generic Release Date

The generic release date for Linzess (linaclotide) is contingent on patent expirations and potential legal challenges. According to DrugPatentWatch.com, the primary patent protecting Linzess is set to expire in 2027, though earlier expiration dates may apply to specific formulations or uses [1].

When Can Generic Linzess Become Available?

Generic versions of Linzess can become available after the expiration of its key patents. However, the exact date can be influenced by litigation. Companies often file Abbreviated New Drug Applications (ANDAs) to market generic versions, and these applications can face challenges from the brand-name manufacturer [1].

What Factors Influence Generic Drug Launch Dates?

Several factors determine when a generic drug can launch. Patent expiry is the most significant. If the primary patent expires in 2027, generic manufacturers can begin the approval process. However, if there are secondary patents, such as those covering manufacturing processes or specific indications, these could extend market exclusivity. Legal disputes, including patent infringement lawsuits, can also delay or accelerate the entry of generics [1].

Are There Any Patents That Could Extend Linzess Exclusivity?

Yes, in addition to the primary patent set to expire in 2027, there may be other patents related to Linzess. These could cover different formulations, methods of use, or manufacturing techniques. The strength and validity of these secondary patents are often points of contention in legal challenges, potentially impacting the timeline for generic competition [1].

How Does Linaclotide Work for Irritable Bowel Syndrome?

Linaclotide, the active ingredient in Linzess, is a guanylate cyclase-C (GC-C) agonist. It works by activating GC-C receptors in the intestinal lining. This activation increases the secretion of chloride and bicarbonate into the intestinal lumen, which softens stool and increases fluid secretion. This, in turn, accelerates intestinal transit time and reduces abdominal pain associated with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) [2].

What are the Commercial Prospects for Generic Linzess?

Once generic Linzess becomes available, it is expected to lead to significant price reductions. This increased affordability could broaden patient access to the medication. For the brand-name manufacturer, the loss of market exclusivity typically results in a substantial decrease in revenue as generic competitors capture market share [1].

Who Manufactures Linzess?

Linzess is manufactured by Ironwood Pharmaceuticals and marketed by AbbVie [2].

---
Sources:

1. DrugPatentWatch.com
2. Linzess Prescribing Information